Actual Medicinal Product (AMP) Zyduco XL 1200mg tablets (Zydus Pharmaceuticals UK Ltd)

Stability Information

(Some stability information inherited from generic)

Stability: There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label.  Mitigation measures may need to be considered.  Keep medicines in MCAs for the shortest time necessary.  Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
Notes: Store in airtight containers and protect from moisture.
Provenance: This compatibility recommendation is derived from Mezavant XL 1200mg tablets (Takeda UK Ltd).
Generic: Mesalazine
Formulation: Mesalazine 1.2g gastro-resistant modified-release tablets